Tina Marriott has served as Board Chair and member of the Revagenix board since 2021.

Ms. Marriott has served as Chief Operating Officer of Recursion since July 2018 and as President since October 2019. She was previously Senior Vice President, Executive Committee member, and Compliance Committee member at Achaogen, a publicly traded biopharmaceutical company that discovered, developed and commercialized treatments for infectious disease from May 2016 to June 2018, where she led Achaogen’s technical operations team—accountable for process development, supply chain and diagnostic development. Prior to Achaogen, she was Global Head of Technical Development Business Operations at Roche from October 2014 to April 2016, where she was responsible for business and technology infrastructure.

She spent a total of 20 years at Genentech/Roche in technical operations roles that included Automation Engineer, Associate Director Manufacturing Sciences, Director Process Development Engineering and Senior Director Technical Development Operations & Engineering. She has both deep technical expertise in scale-up of biopharmaceutical production and managing technical and operational organizations.

Ms. Marriott was recognized by the Healthcare Business Women’s Association as a Rising Star in 2012, was recognized by Utah Business magazine as CXO of the Year in 2020, and was a 2019 Women Tech Council Awards winner. She has served on the advisory board of Colorado State University’s College of Engineering since 2015 and was recognized in 2019 as a CSU Distinguished Alumni. Ms. Marriott received a B.S. in Chemical Engineering from Colorado State University.

Cristina Larkin has served as a member of the Revagenix board since 2023.

Ms. Larkin has over 25 years of experience in senior leadership roles in the biopharmaceutical industry. Most recently, she served as the Chief Operating Officer and a member of the executive team of Spero Therapeutics, a publicly traded biotech company. In this role, she played a key role in helping the company transition from a preclinical private company to a public company with three late-stage clinical assets.

Prior to joining Spero Therapeutics, Ms. Larkin worked as an Assistant Vice President at Allergan (formerly known as Actavis/Forest Labs) from 2004 to 2015. During her tenure, she held various senior leadership positions. From 1994 to 2004, she worked at Ortho-McNeil Pharmaceuticals, a J&J company, where she held various senior leadership roles in marketing, market access, sales, and sales management.

Currently, Ms. Larkin works as an advisor to various investment and biotech companies and is an EIR (Executive in Residence) for Cleveland Clinic Innovations Fund and Columbia Technology Ventures. She also serves as a member of the Board of Directors for APUA, Alliance for Prudent Use of Antibiotics, and Florida State College of Business, BAISSC. Ms. Larkin earned her B.S. from Florida State University.

Michael Lamprecht, PhD, has served as a member of the Revagenix board since 2023.

Dr. Lamprecht is an Investment Associate at Tenmile, based in Sydney, specializing in biotechnology, startups, and early-stage investments. With over 15 years in the field, he has a unique background in developing regulatory and clinical strategies for novel cell-based therapies. His previous roles include Entrepreneur-in-Residence at Xora Innovation, Singapore, and Director of Regulatory Affairs at EpiBone, a U.S. biotech firm pioneering adult stem cell-based bone and cartilage grafts. Dr. Lamprecht holds a PhD in biomedical engineering from Columbia University, along with a bachelor’s degree in biomedical engineering from Boston University.

Bruce Montgomery, MD, has served as a member of the Revagenix board since 2024. Prior to this, he was a board observer in 2021 and an advisor since 2020.

Most recently, Dr. Montgomery served as CEO of Avalyn Pharma and has more than 34 years of life science operations and financing experience. Prior to Avalyn, Dr. Montgomery served as Chief Executive Officer of Cardeas, Senior Vice President of Gilead Sciences, and founder and Chief Executive Officer of Corus Pharma (acquired by Gilead in 2006).  Dr. Montgomery has raised over 250 million dollars in venture and public financings, has over 20 years of public company board service, and is currently on the board of Xencor.

In 1998, Dr. Montgomery was recognized by the FDA Commissioner with a special citation for leadership in the development and approval of TOBI.  For this work, Dr. Montgomery also received the Inventor of the Year award from the University of Washington and received a scientific achievement award from the Cystic Fibrosis Foundation for his work on medications which collectively have extended the average life span of cystic fibrosis patients by over a decade.

Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major [Merck Award]), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle.  In 2012, Dr. Montgomery was honored as one of the top 150 living graduates of the University of Washington College of Arts and Sciences in conjunction with the 150th anniversary of the university. Dr. Montgomery is a board certified internist and pulmonologist.

Ryan Cirz, PhD, has spent the past 22 years focused on the discovery and development of novel antibacterials for high unmet medical needs. At Achaogen, a San Francisco-based biotech which he helped found, he witnessed firsthand the evolution of both the pathogens being targeted and the regulatory framework to obtain market authorization for new, innovative products. While Achaogen grew from academic startup to a >$1B NASDAQ-valued public company, it struggled to find a commercial footing with its breakthrough-therapy-designated lead product. He spent the latter part of his time at Achaogen both overseeing the research pipeline and working closely with the commercial/field team, end-users, charities/NGOs, and government stakeholders to seek to understand the driving forces behind the commercial struggles. He carried those learnings to Revagenix where he continues to focus on extreme unmet medical needs with a lens on solutions to the barriers to patient access and commercial success. Dr. Cirz received his PhD from The Scripps Research Institute and BS from The Pennsylvania State University where he still serves as an industry advisor to the Eberly College of Science.

Andrew McCandlish, PhD, is an experienced leader within corporate/business development and operations across biotechnology, pharmaceuticals, and medical devices/diagnostics.   In his current role as Chief Operating Officer at Revagenix, Dr. McCandlish is accountable for all business areas outside of R&D, including finance/accounting, corporate development, legal, and alliance management.  Previously as Head of US Business Development at pH Pharma, he was responsible for partnering efforts (out/inlicensing, R&D collaborations) for oncology, NASH, and rare disease programs, and as acting VP of Business Development at Meissa Vaccines he negotiated licenses for vaccine candidates, and supported the company’s Series A financing.  At Achaogen, in addition to multiple roles within business development, Dr. McCandlish led efforts to secure federal grant and contract funding and either secured or supported alliance management of approximately $350 million of non-dilutive funding.  He also had operational responsibilities as Project Team Leader for a 14-member cross-functional team developing a therapeutic drug monitoring (TDM) assay successfully deployed in a critical Phase 3 trial, and partnering efforts to secure a partner to commercialize the TDM assay globally.  Dr. McCandlish has also supported efforts to fund multiple biotech and diagnostics companies through private investments, authoring sections of S1/S3s in support of an IPO and follow-on financings, and raised funding from venture capital firms and angel investors.  Dr. McCandlish holds a PhD in Molecular Biology from Princeton University, where he studied outer membrane biogenesis in Escherichia coli in the laboratory of Thomas J. Silhavy, and a BS with Honors from The Ohio State University in Molecular Genetics/Business Marketing (Capital Program).

Lloyd Czaplewski has 30-years of biopharmaceutical and NCE discovery and development experience from concept to clinical evaluation across multiple therapeutic areas – including antiinfective indications. He has built and then sold an antibacterial company, hired outstanding teams, created SABs and has raised >£25m from UK, Europe, USA and Japan. He is an inventor on >25 patents and has authored >40 papers. He is currently the CSO of Persica Pharmaceuticals Ltd which focuses on chronic back pain, and a Founder and Director of Chemical Biology Ventures Ltd which provides consulting services to biotech, academia, charities and investors. Lloyd is an advisor to several international antibacterial groups including CARB-X, the Novo Repair Impact Fund, where he Chairs the SAB, GARDP and the WHO Clinical Pipeline Advisory Group and a non-exec director at Curza. Lloyd holds a PhD in Molecular Genetics from the University of Glasgow and completed further postdoctoral research studies at the University of Leeds.

Ian Friedland, MD, is currently a consultant, focusing on advising companies on early and late  development of anti-infective products. He completed his general medical and pediatric training in South Africa (University of the Witwatersrand, Johannesburg) and completed his pediatric infectious disease fellowship at UT Southwestern Medical Center in Dallas. He served as the Chief Medical oOfficer at Achaogen from 2014 to 2017, where he was responsible for leading the clinical development, regulatory strategy and medical affairs functions. As CMO and consultant he led the successful filing of plazomicin. Prior to Achaogen, Dr. Friedland headed the clinical development of numerous antibiotics at Cubist pharmaceuticals. He has worked in the pharmaceutical and biotechnology industry for 20 years, at both large Pharma (Merck, J&J) and several small biotech companies, leading clinical development teams of several important antibiotics and has played a pivotal role in the development and regulatory submission in the US, EU and other regions of new drugs including ertapenem, caspofungin, doripenem, alvimipan, fidaxomicin, ceftolozane/tazobactam and plazomicin, in addition to supporting many marketed anti-infective agents. He is a frequent participant in FDA/FNIH/PhRMA infectious disease working groups. He is an author on over 100 peer reviewed journal articles and book chapters.

J. Kevin Judice, PhD, currently serves as the co-founder and Chief Executive Officer at DICE Therapeutics. Prior to DICE Therapeutics, Dr. Judice served as Chief Scientific Officer at Cidara Therapeutics, an antifungal company he helped found in 2012. In 2004, Dr. Judice co-founded Achaogen, Inc. (Nasdaq: AKAO), where, as the first employee, he was the Chief Scientific Officer and Chief Executive Officer. During his seven-year tenure at Achaogen, he oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA. Prior to Achaogen, Dr. Judice served as the Vice President of Chemistry at Theravance, where he led the discovery of Vibativ (televancin).

Dr. Judice received his Ph.D. in organic chemistry from the University of California Los Angeles and did his postdoctoral fellowship at the University of California Berkeley. He received his Bachelor of Science in chemistry from Texas A&M University. Dr. Judice is also a Henry Crown Fellow at the Aspen Institute.

Heinz Moser, PhD, heads medicinal, analytical and structural chemistry in Emeryville, supporting the infectious disease portfolio at Novartis until July 2018, switching to protein interactomics with focus on targets that are difficult to drug. Prior to this position, he worked as VP of chemistry at Achaogen, South San Francisco, a small biotech company specializing in antibacterials. Previously, he was CTO and VP of chemistry at Genesoft Pharmaceuticals (later Oscient), a company exploring sequence-specific DNA binding agents as novel therapeutic modality. He started his professional career in 1987 at CIBA Basel in the Central Research Laboratories where he initiated and later headed a project in the field of nucleic acid based therapeutics (antisense). During the merger to form Novartis in 1996 he relocated to Horsham UK, heading the medicinal chemistry department for respiratory diseases.

Dr. Moser received his M.S. in Natural Sciences and Ph.D. in Chemistry from ETH Zurich (A. Eschenmoser) and did postdoctoral research at Caltech (P. Dervan) prior to starting his industrial career. His main professional interests are related to drug discovery and medicinal chemistry and specifically include modulation of protein-protein and nucleic acid-protein interactions, antibacterials, cheminformatics, natural products and interdisciplinary approaches to improve the quality of novel drugs.